
AbbVie nears $10.9B deal to buy Apogee Therapeutics for new eczema drug
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, pote...

